-
United Therapeutics Corporation v. Liquidia Technologies, Inc. DC CAFC
- 1:20-cv-00755
- D. Del.
- Judge: Richard G. Andrews
- Filed: 06/04/2020
- Closed: 09/09/2022
- Latest Docket Entry: 04/17/2024
- PACER
- Docket updated daily
1
Plaintiff
1
Defendant
1
Accused
Product
2
Patents-in-Suit
828
Days in
Litigation
-
United Therapeutics Corporation v. Liquidia Technologies, Inc. DC CAFC
- 1:20-cv-00755
- D. Del.
- Judge: Richard G. Andrews
- Filed: 06/04/2020
- Closed: 09/09/2022
- Latest Docket Entry: 04/17/2024
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A pharmaceutical composition comprising treprostinil or a pharmaceutically acceptable salt thereof, said composition prepared by a process comprising providing a starting batch of treprostinil having one or more impurities resulting from prior
view more
|
Invalid
Entry 480 Entry 436 |
2 |
The pharmaceutical composition of claim 1, wherein the salt is isolated in crystalline form.
|
Invalid
Entry 480 Entry 436 |
3 |
The pharmaceutical composition of claim 1, wherein the base is selected from the group consisting of sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, and choline.
|
Invalid
Entry 480 Entry 436 |
6 |
The pharmaceutical composition of claim 1, wherein the isolated salt is stored at ambient temperature.
|
Invalid
Entry 480 Entry 436 |
9 |
A pharmaceutical product prepared by the process of claim 8.
|
Invalid
Entry 480 Entry 436 |
-
Infringement
Liquidia Technologies, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Version of Treprostinil Inhalation 0.6 mg/mL | US 9,593,066 B2 |
6, 8, 9
|
No infringement
Entry 436
|